Australia’s ChemGenex High On Leukemia Drug After Trial Results
This article was originally published in PharmAsia News
Executive Summary
ChemGenex of Australia said the latest trial results of its omacetaxine drug to treat chronic myeloid leukemia are so promising it expects the medicine to be on the U.S. market by next March. The new results show an 85 percent remission rate for trial participants who are resistant to standard treatments, ChemGenex said. Analysts see the U.S. market for its drug worth $250 million in 2012 alone. CEO Greg Collier said that based on the positive results, the firm already is interviewing for a chief commercial officer to market the drug. (Click here for more
You may also be interested in...
EU Experts Want One-Stop-Shop EU Governance That Mimics Best Of Other Jurisdictions
It may be blue sky thinking to surmise how a new EU medtech regulatory governance structure could evolve. But with change on the horizon, experts see exciting opportunities.
How Ochre Bio Bagged Boehringer For Its RNA-Based Regenerative MASH Therapies
UK-based Ochre Bio has signed its first major deal with Boehringer Ingelheim. Scrip talked to its co-founder and CEO, Jack O’Meara, about its human tissue-based drug discovery platform, its resulting RNA platform for liver disease and how the fledgling drug company's early work mirrored that seen in diagnostics.
IGI Bets On Trispecific Antibody To Make Inroads Into Big Pharma Myeloma Turf
Ichnos Glenmark Innovation’s president and CEO talks to Scrip about the promising activity profile of the alliance’s early stage trispecific antibody versus Janssen’s teclistamab and also maintains that the setback for Gilead’s magrolimab hasn’t eclipsed prospects for its bispecific antibody.